

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

YAGITA, Akikuni

Appln. No.: 09/447,049

Confirmation No.: Unknown

Group Art Unit: 1651

Filed: November 23, 1999

Examiner: F. PRATS

For: INTERLEUKIN-12 INDUCER AND MEDICAL COMPOSITION

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Amend the specification by inserting before the first line the sentence:

This is a divisional of Application No. 09/447,049 filed November 23, 1999, which is a divisional of Application No. 08/967,821, filed November 12, 1997, now patent No. 6,238,660; the disclosure of which is incorporated herein by reference.

IN THE CLAIMS:

Please cancel claims 1-17 without prejudice or disclaimer and add the following claims 18-20.

Please add the following claims.

PRELIMINARY AMENDMENT
DIVISIONAL OF 09/447,049

--18. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC to the patient.

19. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC and components of fungal mycelium to the patient.

20. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC, components of fungal mycelium and components of hemolytic streptococci to the patient.--

[illegible]

Respectfully submitted,

Louis Gubinsky

Date: December 3, 2001

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The specification is changed as follows:

Amend the specification by inserting before the first line the sentence:

This is a divisional of Application No. 09/447,049 filed November 23, 1999, which is a divisional of Application No. 08/967,821, filed November 12, 1997, now patent No. 6,238,660; the disclosure of which is incorporated herein by reference.

IN THE CLAIMS:

Claims 1-17 are canceled.

Claims 18-20 are added as new claims.

--18. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC to the patient.

19. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC and components of fungal mycelium to the patient.

20. A method of inducing IL-12 in a patient in vivo that comprises orally administering AHCC, components of fungal mycelium and components of hemolytic streptococci to the patient.--